Compare Marathon Petroleum Corp (MPC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs TG Therapeutics Inc — how do they compare? Marathon Petroleum Corp trades at $348.5 (market cap $94.48B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Marathon Petroleum Corp is far larger — about 12.4× TG Therapeutics Inc's market cap, and Marathon Petroleum Corp pays a 1.19% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MPC | TGTX | |
|---|---|---|
Market Cap | $94.48B | $7.64B |
Sector | Energy | Health |
52-Week High | $336.42 | $59.06 |
52-Week Low | $159.11 | $26.94 |
Enterprise Value | $121.00B | $7.84B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $345.68, up 7.92% over 24 hours, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with a P/E of 11.67 and ROE of 47.9%, supported by recent earnings beats including Q2 2026 EPS of $17.73 versus $14.27 expected. Refining margins remain elevated due to global supply constraints, driving revenue growth projections to $153.6B for 2026.
MPC presents a compelling investment case with strong cash flow generation and shareholder returns via dividends and buybacks. Key risks include exposure to volatile energy markets and geopolitical factors affecting refining margins. Wall Street maintains strong bullish consensus with 76% buy ratings and $332.70 price target, though current price exceeds consensus.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
